Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy (JACC: CardioOncology December 2021-2)

Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy

Cardiorespiratory fitness (CRF) is reduced in cancer survivors and predicts cardiovascular disease (CVD)–related and all-cause mortality. However, routine measurement of CRF is not always feasible.The purpose of this study was to identify clinical, cardiac biomarker, and imaging measures associated with reduced peak oxygen consumption (VO2peak) (measure of CRF) early post–breast cancer therapy to help inform CVD risk.

JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Authors
Alis Bonsignore, RKIN, PhD
Scott C. Adams, RKIN, PhD
Paaladinesh Thavendiranathan, MD, SM

Important Dates

Date of Release: December 21, 2021
Term of Approval/Date of CME/MOC/ECME Expiration: December 20, 2022

Summary


Availability:	On-Demand
	Expires on Dec 20, 2022


Cost:	FREE

Credit Offered:

1 CME Credit

1 ABIM-MOC Point

1 ECME Credit